Ignite Creation Date:
2025-12-25 @ 2:47 AM
Ignite Modification Date:
2025-12-31 @ 11:48 PM
Study NCT ID:
NCT05844033
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-25
First Post:
2023-04-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Biomarker for Infection Risk in CLL and MM
Sponsor:
Massachusetts General Hospital
Organization:
Study Overview
Official Title:
Biomarker for Infection Risk in Chronic Lymphocytic Leukemia and Multiple Myeloma
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2025-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this research study is to use advanced immunology laboratory analysis to identify a more precise blood test that will predict infection risk in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) or Multiple Myeloma (MM).
Detailed Description:
The goal of this research study is to identify an antigen-specific antibody profiling biomarker associated with increased risk of any infections in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) or Multiple Myeloma (MM).
Research procedures including screening for eligibility, clinic visits, and blood tests.
This involves performing blood tests which detect antibodies directed against specific pathogens and measure their functional capacity, and collecting information about outcomes in patients.
Participation in this research study is expected to last 2 years.
It is expected that about 150 people CLL or MM will take part in this research study, and this will predominantly include people with CLL/SLL.
Takeda is supporting this research study by providing funding.
Research procedures including screening for eligibility, clinic visits, and blood tests.
This involves performing blood tests which detect antibodies directed against specific pathogens and measure their functional capacity, and collecting information about outcomes in patients.
Participation in this research study is expected to last 2 years.
It is expected that about 150 people CLL or MM will take part in this research study, and this will predominantly include people with CLL/SLL.
Takeda is supporting this research study by providing funding.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: